{
    "clinical_study": {
        "@rank": "70577", 
        "arm_group": {
            "arm_group_label": "Telavancin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label, single-dose pharmacokinetic (PK) study.  Infants,\n      children, and adolescents will receive a single 10 mg/kg dose of telavancin infused\n      intravenously (IV) over 60 minutes"
        }, 
        "brief_title": "An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gram-Positive Bacterial Infections", 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Gram-Positive Bacterial Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subject is 1 to 17 years (inclusive) and has a height/length/weight (for subjects between\n        12 and 23 months) or body mass index (BMI, for subjects 2 to 17 years) within the 5th to\n        95th percentile (inclusive) for age and sex.\n\n        Subject requires intravenous antibiotics for:\n\n          -  Gram-positive bacterial infection OR\n\n          -  prophylaxis of Gram-positive infection OR\n\n          -  empiric therapy for suspected Gram-positive infection\n\n        Exclusion Criteria:\n\n        Subject has an estimated creatinine clearance <50 mL/min/1.73 m2 (Schwartz formula).\n\n        Subject has a history of allergies or hypersensitivities to glycopeptide antibiotics\n        (e.g., vancomycin), telavancin, or the formulation excipients.\n\n        Subject requires concomitant vancomycin treatment.\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013141", 
            "org_study_id": "0101"
        }, 
        "intervention": {
            "arm_group_label": "Telavancin", 
            "intervention_name": "Telavancin", 
            "intervention_type": "Drug", 
            "other_name": "VIBATIV"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gram positive bacteria", 
            "Telavancin", 
            "VIBATIV", 
            "Pediatric", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "last_name": "TBD TBD"
            }, 
            "facility": {
                "address": {
                    "city": "TBD", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94080"
                }, 
                "name": "TBD"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years", 
        "overall_contact": {
            "email": "Fheerinckx@theravance.com", 
            "last_name": "Frederic Heerinckx", 
            "phone": "650-808-6400"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics- AUC", 
            "safety_issue": "No", 
            "time_frame": "48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013141"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics- Cmax", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Pharmacokinetics- Tmax", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Pharmacokinetics- t1/2", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Pharmacokinetics- CLp", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "AEs", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}